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Vesicants are potent blistering agents. The prototype vesicant is sulphur mustard gas, ﬁ rst used in World 
War I, which still has no effective antidote. We used a mustard gas surrogate 2-chloroethyl ethyl sulphide 
(CEES) to study the ability of resveratrol (RES) and pterostilbene (PTS), two well-established stilbene 
antioxidants, ebselen (EB-1), an organoselenium compound, and three EB-1 analogues (EB-2, EB-3, and 
EB-4) to reduce CEES toxicity in human epidermoid carcinoma cells (A-431). Following a 24-hour 
incubation of a toxic concentration of CEES (1000 μmol L-1), we used the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] test to analyse cell viability. Different concentrations of test 
antioxidants alone (15 μmol L-1, 30 μmol L-1 or 60 μmol L-1) did not decrease cell viability. Treatment with 
CEES and test antioxidants for 24 h showed that only EB-1 and its analogues EB-2, EB-3, and EB-4 but 
not the stilbene compounds could rescue the cells from death. EB-1 and EB-4 were the most effective at 
reducing CEES cytotoxicity and did so in a concentration-dependent manner, while EB-2 and EB-3 
demonstrated the least protective effect. In summary, the data described herein indicate that organoselenium 
antioxidants, especially EB-4, may prove useful as countermeasures to blistering agents.
KEY WORDS: CEES, cell viability, EB-1, EB-2, EB-3, EB-4, human epidermoid carcinoma cells, MTT 
test, organoselenium, pterostilbene, resveratrol, vesicant countermeasure
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During the First World War, a sulphur mustard 
compound known as bis(2-chloroethyl)sulﬁ de and 
commonly referred to as mustard gas was developed 
into a weapon and has since been used in a number of 
world conﬂ icts. Mustard gas and its analogues have a 
vesicant or blistering capacity when applied to skin 
(1, 2). The resulting blisters are slow to heal and pose 
the risk of secondary infection. Mustard gas also 
exhibits a wide array of toxicities. From a chemical 
point of view, vesicants are relatively simple to 
synthesize and exposure to weapons-grade mustards 
on the battleﬁ eld or in a civilian setting could overload 
available emergency services (3) and become difﬁ cult 
to manage, since no specific antidote has been 
developed to control mustard toxicity. Thus, an 
effective countermeasure to mustard gas toxicity 
would be beneﬁ cial to the public health.
In addition to causing DNA alkylation, mustards 
also readily bind to cellular thiols; particularly the free 
thiol group of the cysteine residue within the cellular 
antioxidant glutathione (GSH). As GSH is neutralised 
by mustards, the cell becomes increasingly more 
sensitive to oxidative stress (4). Oxidative stress can 
lead to cell death when the production of reactive 
oxygen (ROS) and/or reactive nitrogen oxide species 
(RNOS) exceeds the capacity of cellular antioxidant 
defence mechanisms (5, 6). In recent years, the idea 
of using antioxidants to decrease the toxicity of 
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vesicants has gained momentum through results 
obtained from in vivo (7, 8) and in vitro studies (9-12). 
While these antioxidants may serve as effective 
countermeasures to mustard toxicity in various 
experimental models, none of them have evolved into 
an effective therapy to date.
This report describes the results of a study in which 
several compounds with established or suspected 
antioxidant activities were tested for ability to reduce 
the toxicity of a sulphur mustard surrogate in vitro. 
These compounds, from this point forward designated 
as the test compounds, were resveratrol (RES), 
pterostilbene (PTS), ebselen (EB-1), and three EB-1 
analogues (EB-2, EB-3 and EB-4) which, although 
not as extensively studied as the parent compound, 
exhibit structural features common to organoselenium 
compounds with antioxidant activity (13, 14). Since 
working with mustard gas poses a signiﬁ cant risk to 
the investigator and is not commercially available, we 
used an analogue of mustard gas instead, that is, 2-
chloroethyl ethyl sulphide (CEES). This compound is 
commonly referred to as half mustard due to the 
presence of a single chloroethyl group and forms only 
monofunctional adducts with DNA. We selected 
human epidermoid carcinoma cells (A-431) to study 
the ability of the test compounds to reduce CEES 
toxicity. This cell line has been used in various in vitro 
dermatological studies, as it provides an affordable 




A-431 human epidermoid carcinoma cells (ATCC 
#CRL-1555) (18) were purchased from the American 
Type Culture Collection (Manassas, VA, USA).
Treatment compounds
Unless otherwise indicated, all treatment 
compounds were purchased from Sigma-Aldrich (St. 
Louis, MO, USA), as follows: half-mustard (CEES, 
cat # 242640), resveratrol (RES, 3,4`,5-trihydroxy-
trans-stilbene, cat # R5010) and pterostilbene (PTS, 
3,5-dimethoxy-4`-hydroxy-trans-stilbene, cat # 
P1499). Ebselen (EB-1; 2-phenyl-1, 2-benzisoselenazol-
3(2H)-one, cat # 70530) and ebselen oxide (EB-3, cat 
#10012298) were purchased from the Cayman 
Chemical Company (Ann Arbor, Michigan, USA). 
Ebselen analogues (EB-2 and EB-4) were synthesized 
as described previously (19). The chemical structures 
of CEES and the compounds tested are shown in 
Figure 1.
Figure 1  Structure of CEES and of the tested antioxidant 
compounds
Chemicals and other reagents
Unless otherwise indicated, all chemicals used in 
the study were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and included dimethylsulphoxide 
(DMSO, cat # D8418), 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT, cat # 
M2128), Triton-X100( cat # T8787), BSA (cat # 
A7906), phosphate buffered saline (PBS, cat # P3813), 
tris-hydroxymethylaminomethane (TRIS, cat # 
154563), phenol solution (cat # P4557), chloroform: 
isoamyl alcohol (cat #C0549), EDTA (cat # E0399), 
agarose (cat # A9539), glacial acetic acid (cat # 
242853), and glycerol (cat # G5516). Elutriation buffer 
(cat # 19086) was purchased from Qiagen, Inc. 
(Valencia, CA, USA). Trypan blue dye (cat # 
BDH8721-0) was obtained from VWR International 
(West Chester, PA, USA). Potassium acetate (cat # 
529543), ethidium bromide (cat # EM- 4410), NaCl 
(cat #EM- 7710), and boric acid (cat # EM-203667) 
were purchased from EMD Chemicals (Gibbstown, 
NJ, USA).
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Cell culturing medium
Cells were grown in tissue culture dishes in 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing phenol red, L-glutamine, glucose 4.5 mg L-1, 
and 10 % heat-inactivated foetal bovine serum (FBS) 
and were supplemented with 50 μg mL-1 of gentamicin 
(cat # 15750-060; Invitrogen, Carlsbad, CA, USA). 
Complete DMEM was obtained by mixing 50 mL of 
FBS and 550 μL of gentamicin. A-431 skin cells were 
briefly trypsinised prior to passaging (Invitrogen 
Corporation, Carlsbad, CA, USA, cat # 10564). Cells 
were treated in DMEM containing L-glutamine and 
glucose, but not phenol red and FBS (clear DMEM) 
(Invitrogen Corporation, Carlsbad, CA, USA; cat # 
25300-054).
Assays to determine cellular viability
We mixed 347 μL of CEES with 9.6 mL of ethanol 
to yield a 300 mmol L-1 stock solution and stored it at 
4 °C until needed. RES (14.8 mg) was dissolved in 
DMSO (648 μL) to make a 100 mmol L-1 stock 
solution. PTS (208.8 mg) was dissolved in 8125 μL 
of DMSO and EB-1 (10 mg) was dissolved in 364 μL 
of DMSO to yield 100 μmol L-1 solutions. Next, 
4.7 mg of EB-2 was dissolved in DMSO (167 μL) and 
gently heated. In addition, 2.9 mg of EB-3 and 6.9 mg 
EB-4 were dissolved in DMSO (172.4 μL and 250 μL, 
respectively) to make a 100 mmol L-1 stock solution 
of each. Finally, all the test compounds (100 mmol 
L-1) were dissolved in an appropriate amount of DMSO 
to make a ﬁ nal stock solution of 60 mmol L-1 and were 
stored at -20 °C until treatment.
MTT reagent was prepared by mixing 0.04 g of 
thiazolyl blue tetrazolium bromide powder with 8 mL 
of FBS–free, phenol-free DMEM to yield a ﬁ nal 
concentration of 5 mg mL-1. MTT solubilisation 
reagent was prepared by mixing 270 mL of isopropyl 
alcohol, 30 mL Triton-X, and 30 mL of 1 mol L-1 HCl 
in a glass amber bottle and was stored at room 
temperature. 
A-431 skin cells were seeded into 24-well plates 
(1x105 cells per well) and treated the next day. Culture 
medium containing FBS was removed from each well 
and replaced with 0.5 mL of FBS- and phenol red-free 
DMEM containing either 0 (control), 15 μmol L-1, 
30 μmol L-1, or 60 μmol L-1 of each test compound. Cells 
were then incubated in parallel with or without CEES 
(1000 μmol L-1). After 24 h, the MTT viability assay was 
conducted. All treatments were performed in triplicate 
wells for each test compound, and all experiments were 
performed a minimum of three times each.
Control wells were supplemented with 0.1 % of 
DMSO. This concentration of vehicle was neither 
toxic nor inhibitory in the MTT assay (data not 
shown).
The MTT assay measures the conversion of 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) into a coloured product in living cells. 
To determine the viability of cells, the MTT assay was 
performed as described by Mosmann (20), with the 
incubation time of the MTT reagent being modiﬁ ed 
as described by Shah et al. (21). To 500 μL of culture 
medium we added 50 μL of MTT and let it incubate 
at 37 °C for 1 h. Next we added 550 μL of MTT 
solubilisation reagent, mixed the wells, and let it 
incubate for another 10 min, still at 37 °C. The optical 
density of this purple formazan product was then 
measured spectrophotometrically in a glass cuvette at 
570 nm. The MTT reagent did not react with any of 
the test compounds at the concentrations used in the 
absence of cells (data not shown), which validates its 
use for cell viability studies.
To determine whether or not EB-1 could reduce 
CEES toxicity in a viability assay not related to the 
MTT assay, A-431 cells were plated in 6-well plates 
(1x106 cells per well). The following day, culture 
medium was removed from triplicate wells and 
replaced with FBS and phenol red-free DMEM 
containing either the DMSO vehicle (0.1 %) or CEES 
(1000 μmol L-1) in the presence or absence of EB-1 
(15 μmol L-1, 30 μmol L-1 or 60 μmol L-1). After 24 h, 
culture medium was removed from all wells and the 
wells were washed once with PBS. Next, 500 μL of 
trypsin was added to each well and incubated for 10 
min at 37 °C. Cells were collected in a microfuge tube 
and spun in a table top centrifuge at 1957 x g for 5 
min. The supernatant was removed and 500 μL of FBS 
and phenol red-free DMEM was used to re-suspend 
the cell pellet. Next, 50 μL of the re-suspended sample 
was added to an equal volume of trypan blue in a new 
microfuge tube. Finally, 10 μL of this combined 
solution was applied to a haemocytometer, which was 
inspected with a standard light microscope at 20x 
magniﬁ cation. Cells without the dye were counted as 
viable and the number of viable cells per treatment 
was evaluated.
CEES-induced DNA fragmentation
A-431 skin cells were grown to 90 % conﬂ uency 
in complete DMEM in 6-well plates (1x106 cells per 
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well). The next day, the culture medium was removed 
and separate wells were incubated with 2 mL of FBS- 
and phenol-red free DMEM containing different 
concentrations of CEES (0, 250, 500, 1000, 1500, and 
2000) μmol L-1. These plates were then incubated at 
37° C for 16 h to 18 h. DNA fragments were then 
isolated and analysed according to the method reported 
by our lab previously (12).
Log P determination for EB-1 and its analogues
Log P, or the logarithmic partition coefﬁ cient of 
1-octanol/water, is a critical tool in the determination 
of drug membrane permeability. This value is used to 
estimate properties such as absorption, metabolism, 
and bioavailability (22). It is worth noting that all log 
P values for the organoselenium compounds reported 
in the Results section were obtained using the 
Molinspiration Property Calculation Service (www.
molinspiration.com) and were not experimentally 
determined.
Statistical analysis
All experiments were carried out in triplicate, with 
the results being reported as the mean ± standard error 
of the mean from at least three representative 
experiments. Statistical comparisons were made using 
either Student’s t-test (for comparison between two 
groups) or one-way ANOVA with Neumann-Keuls 
post hoc test (for comparison across multiple groups) 
using GraphPad Prism 4.0® software (GraphPad 
Software, Inc., San Diego, CA, USA). Differences 
were considered to be signiﬁ cant at p<0.05.
RESULTS
CEES cytotoxicity in A-431 cells
At a CEES concentration of 1000 μmol L-1, the 
MTT assay found ~7 % of the cells viable (Table 1), 
whereas the trypan blue dye exclusion method found 
~14 % of the cells viable (Table 2). Based on this 
observation, and to ensure a robust toxicity, MTT 
viability studies with CEES were performed at a cell 
density of 1x105 cells per well and a concentration of 
1000 μmol L-1.
CEES-induced DNA fragmentation
DNA fragments from control and CEES-treated 
cells [(250, 500, 1000, 1500 or 2000) μmol L-1] were 
isolated and extracted using phenol/chloroform, 
treated with RNase, and analysed using agarose gel 
electrophoresis. CEES caused a concentration-
dependent increase in DNA fragmentation, with the 
highest fragmentation patterns occurring at 
1500 μmol L-1 and 2000 μmol L-1 CEES concentrations 
(Figure 2).
Test compounds to counteract the toxicity of CEES
RES is a naturally occurring stilbene and antioxidant 
and is polyphenolic in nature (Figure 1). When 
administered alone, RES was not toxic to the skin cells 
at any of the test concentrations at 24 h (Table 1). 
When administered in combination with CEES, RES 
did not rescue the cells from death (Table 1). Similar 
data were obtained for PTS (Table 1).
In contrast, EB-1 exhibited a concentration-
dependent increase in survival reaching about 67 % 
viability at 60 μmol L-1 (Table 1). Only the lowest 
concentration showed no significant increase in 
viability. In addition, EB-1 alone exhibited no toxicity 
to the skin cells at 24 h; moreover, at its highest 
concentration EB-1 significantly increased cell 
viability (p<0.001) compared to vehicle-treated cells 
(Table 1).
EB-2 significantly increased MTT activity at 
60 μmol L-1 (~10 %) in the absence of CEES co-
treatment. In addition, only the 60 μmol L-1 
concentration of EB-2 provided signiﬁ cant (p<0.001) 
protection against CEES (Table 1).
EB-3 alone signiﬁ cantly increased A-431 cell 
viability across the range of test concentrations, but 
in terms of protection against CEES, only the highest 
concentration was signiﬁ cantly effective (Table 1).
Figure 2  DNA fragmentation in A-431 skin cells resulting from 
treatment with CEES. Lane 1, DNA 1 kb marker; 
lane 2, control; lane 3, 250 μmol L-1 of CEES; lane 
4, 500 μmol L-1 of CEES; lane 5, 1000 μmol L-1 of 
CEES; lane 6, 1500 μmol L-1 of CEES; lane 7, 
2000 μmol L-1 of CEES
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EB-4 in turn showed an 18 % to 23 % increase in 
cell viability when given alone, and in combination 
with CEES it showed signiﬁ cant protection at all three 
concentrations (Table 1).
In summary, all of the EB analogues showed some 
degree of action against CEES cytotoxicity in A-431 
skin cells, but EB-4 showed the highest cytoprotective 
potential.
The trypan blue dye exclusion method conﬁ rmed 
EB-1 efficiency against CEES toxicity without 
signiﬁ cantly increasing cell viability when given alone 
(Table 2). The data obtained with the trypan blue dye 
exclusion assay showed higher standard errors than 
data obtained with the MTT assay, which may be 
attributed to the extensive sample handling required 
for the trypan assay and the difﬁ culty to distinguish 
which cells are truly excluding the dye, as some cells 
appear light blue under the microscope and confound 
scoring.
Log P values were 2.92 for EB-1, 2.10 for EB-2, 
2.88 for EB-3, and 2.44 for EB-4. We established no 
relationship between lipophilicity, as indicated by log 
P values, and protection against CEES; however, a 
more extensive analysis of lipophilicity and 
countermeasure effectiveness is warranted before any 
conclusions are drawn.
Table 1  Effects of selected test compounds on the cytotoxicity of CEES in A-431 skin cells, as determined by the MTT viability 
assay
Treatment a Viability / % b
Untreated c                                                                        CEES-treatedd
Control 100 6.73±1.06
RES
RES (15 μmol L-1)
RES (30 μmol L-1)








PTS (15 μmol L-1)
PTS (30 μmol L-1)








EB-1 (15 μmol L-1)
EB-1 (30 μmol L-1)








EB-2 (15 μmol L-1)
EB-2 (30 μmol L-1)








EB-3 (15 μmol L-1)
EB-3 (30 μmol L-1)








EB-4 (15 μmol L-1)
EB-4 (30 μmol L-1)







a All cells were cultured for 24 h in the absence or presence of CEES
b Values represent the mean ± standard error of the mean from three independent experiments
c Signiﬁ cantly different from untreated control cells (vehicle) at *p<0.05 , **p<0.01 or ***p<0.001 by Student’s t-test and 
ANOVA
d Signiﬁ cantly different from CEES-treated control cells at ^p<0.05 or ^^^p<0.001 by Student’s t-test and ANOVA
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DISCUSSION
It has been nearly one hundred years since mustards 
were ﬁ rst used as chemical warfare agents, yet an 
effective medical countermeasure is still sought after 
(23, 24). The cellular mechanisms involved in mustard 
toxicity are well established and include oxidative 
stress, DNA damage, and the overactivation of PARP-
1 (5, 25, 26). The goal of the present research was to 
determine if the selected test compounds could reduce 
the toxicity of a sulphur mustard surrogate in vitro. 
The toxicant used in our studies, CEES, is a 
monofunctional alkylating agent with vesicant activity 
in vivo. CEES has been utilised by other laboratories 
to mimic the effects induced by mustard gas (27, 28). 
The test compounds we used included established 
antioxidants (RES, PTS and EB-1) and three less 
studied organoselenium agents (EB-2, EB-3, and EB-
4) bearing structural similarity to EB-1.
A-431 human epidermoid carcinoma cells are an 
inexpensive and easy alternative to using primary skin 
cell cultures (9, 12, 15, 16). An important limitation 
with this cell line is that it is tumour-derived and 
expresses a mutant p53 protein (29, 30). It is therefore 
possible that these cells respond differently to mustards 
than normal skin cells would, and this possibility 
should not be overlooked. In addition, A-431 cells 
exposed to mustards in vitro are unable to mimic the 
response of normal skin tissue to mustard exposure, 
which becomes injured and forms ﬂ uid-ﬁ lled blisters. 
In spite of these limitations, the A-431 cells make an 
important screening tool for potential countermeasures 
to mustards that can be tested in vivo.
We observed that RES and PTS exhibited no 
propensity to protect A-431 skin cells from mustard 
toxicity. RES has been found in at least one in vivo 
study to protect the lungs from mustard injury (8). 
This discrepancy may be due to the cell type tested 
here or to not having used a high enough concentration 
of the stilbene. The latter however is unlikely, as 
Radkar et al. (17) found that RES exhibited toxicity 
in the same cell line with an LC50 of ~ 60 μmol L
-1. 
PTS was also unable to reduce or prevent mustard 
toxicity in A-431 cells, in contrast to Pereko et al. (31), 
who found it effective in reducing extracellular 
reactive oxygen species.
We obtained the best anti-mustard effects with 
organoseleniums. These compounds contain at least 
one carbon-selenium bond and are not to be confused 
with inorganic selenium, which is a trace element in 
the human diet and has been studied extensively 
against cancer, immunity and infectious/inﬂ ammatory 
diseases (19, 32). Whereas the prototype organoselenium 
compound EB-1 has already been reported to protect 
A-431 skin cells from CEES toxicity (12), the ability 
of the related compounds EB-2, EB-3, and EB-4 to 
do so has not been studied so far to the best of our 
knowledge.  The reason why we turned to 
organoselenium analogues as potential countermeasures 
to CEES toxicity lies in certain limitations of EB-1. 
For one, EB-1 binds strongly to plasma proteins when 
administered intravenously and can not reach the cell 
in the albumin-bound state. It takes thiol-containing 
reducing agents to free EB-1 to bind to membrane-
associated proteins (33). Moreover, the anti-
inﬂ ammatory activity of EB-1 is not likely to be 
involved in the protection against mustard toxicity 
observed in this study because like other in vitro 
models, A-431 skin cells do not possess a vasculature, 
connective tissue, or immune cells. As EB-1 highly 
reacts with protein thiols, its in vitro inhibitory activity 
may be related to nonspeciﬁ c protein interactions (34). 
Lastly, EB-1 may inhibit the oxidative burst mechanism 
used by neutrophils and macrophages during an 
inﬂ ammatory response. The idea that EB-1 can exert 
an immunosuppressive effect in vivo has been explored 
Table 2 Effect of EB-1 on the cytotoxicity of CEES in A-431 skin cells, as determined by the trypan blue dye exclusion assay




EB-1 (15 μmol L-1) 117.30±8.99 5.89±2.55
EB-1 (30 μmol L-1) 71.90±8.19 45.55±7.03*
EB-1 (60 μmol L-1) 76.96±13.14 39.35±11.51*
a All cells were cultured for 24 h in the absence or presence of CEES
b Values represent the mean ± standard error of the mean from three independent experiments
c Signiﬁ cantly different from CEES- treated control cells at *p<0.05 by Student’s t-test and ANOVA
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previously (35). A similar adverse effect on the 
immune system is known to be induced by mustard 
agents. Thus, the combined effect of mustard and EB-
1 on immunity may delay healing in the afﬂ icted 
patient.
In the present study, all three EB-1 analogues 
reduced CEES toxicity in A-431 cells, with EB-4 
exhibiting the highest degree of protection. Masumoto 
and Sies (36) suggest that EB-3 may be converted to 
EB-1 in the presence of intracellular glutathione, but 
our data do not strongly support this hypothesis, as 
we would have observed a higher degree of 
cytoprotection by EB-3 if it had been converted to 
EB-1. Further investigation is required to determine 
whether EB-3 can serve as an EB-1 prodrug or if it 
exerts unique anti-mustard activity.
It is worth noting that we established no relationship 
between anti-mustard action of the organoselenium 
compounds tested here and hydrophobicity, as 
measured by Log P. In an attempt to take advantage 
of the antioxidant potential of EB-1 while minimizing 
its pharmacological shortcomings, numerous analogues 
of EB-1, including those studied in this work, have 
been synthesised, with various structural substitutions 
(19, 37, 38). Alterations to hydrophilicity have been 
introduced to increase water solubility and 
bioavailability of EB-1, which may be even more 
suitable for in vivo applications (39). Hopefully these 
new EB-1 analogues will be more efﬁ cient in an 
animal model, while maintaining the potency 
equivalent to or greater than EB-1.
It is wise to exercise caution when interpreting the 
data obtained using selenium compounds in MTT 
assays. A recent study by Olm et al. (40) indicated that 
selenite toxicity in cancer cells depended on 
extracellular reduction by thiols such as cysteine. In 
our study, the test compounds did not reduce MTT 
reagent in a cell free system at concentrations up to 
and including 60 μmol L-1 (data not shown). Even so, 
these compounds may affect extracellular thiol levels. 
If they do, our in vitro system could reduce MTT 
reagent, produce false positive results, and give the 
appearance of protection. This may to some extent 
explain why cells treated with the organoselenium test 
compounds alone all exhibited higher viability at the 
highest concentrations than vehicle-treated control 
cells. Future studies should inquire whether the 
increased viability observed in the absence of CEES 
for EB-1 and its analogues may be due to an increase 
in extracellular thiols.
One reason why MTT experiments were carried 
out in a culture medium lacking FBS was to minimise 
any interference from FBS components such as 
albumin (41). Even though we did not assess the 
effects of EB-1 on extracellular redox, Schroterova et 
al. (42) found that MTT assays provide a reliable 
measure of cell viability in colon cancer cells exposed 
to diverse selenium-containing compounds at 
concentrations up to 256 μmol L-1.
We also ran the trypan blue dye exclusion to 
determine if a non-mitochondrial based assay can 
measure cytoprotection of organoselenium compounds 
such as EB-1 against CEES. Although it conﬁ rmed 
that EB-1 protected against CEES, viability of cells 
treated with EB-1 alone did not increase compared to 
vehicle-treated controls. The reason is unclear but may 
be related to low level thiol secretion from 
organoselenium-treated skin cells. Nonetheless, both 
viability assays showed that EB-1 protected A-431 
skin cells from CEES toxicity.
Although our present study did not determine the 
mechanism of protection by the organoselenium 
compounds against CEES toxicity, Kim et al. (43) 
have suggested that EB-1 activates nuclear transcription 
via Nrf2. This in turn increases the expression of many 
phase II enzymes such as heme oxygenase (HO-1), 
NAD(P)H:quinone oxidoreductase, and gamma-
glutamylcysteine synthetase (gamma-GCS), which 
act against oxidants. Knocking down Nrf2 in the A-
431 cells with siRNA would likely abolish the 
protective effects of EB-1 and its analogues, and future 
studies may be looking in that direction.
EB-1 is also known to possess a glutathione 
peroxidase-like activity (44), and this mechanism of 
protection cannot be ruled out for EB-1 and its 
analogues.
In summary, EB-1 and its analogues show a 
potential against mustard toxicity. Previous studies 
demonstrated the effectiveness of EB-1 in vitro (9, 10, 
12), this study is the first to propose novel 
organoselenium compounds (EB-2, EB-3, and EB-4) 
as agents against mustard toxicity. EB-4 showed the 
greatest degree of protection against CEES-induced 
toxicity of all the compounds in this class. Our future 
studies will investigate whether organoselenium 
analogues of EB-1 are more efﬁ cient in an animal 
model in comparison with other pharmaceuticals such 
as topical steroids. We will also look into the 
mechanisms of protection that these organoselenium 
compounds provide against CEES toxicity.
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Sažetak
ANALOZI EPSELENA SMANJUJU TOKSIČNOST 2-KLOROETIL ETILNOG SULFIDA U A-431-
STANICAMA
Plikavci izazivaju izražene mjehuriće na koži. Najpoznatiji je svakako sumporni iperit, koji se prvi put 
uporabio u 1. svjetskom ratu i do današnjega dana nema djelotvornog protuotrova. U ispitivanju smo rabili 
zamjenu za iperit, 2-kloroetil etilni sulﬁ d (CEES) da bismo testirali sposobnost resveratrola (RES) i 
pterostilbena (PTS), dvaju poznatih stilbenskih antioksidansa, organoselenijeva spoja epselena (EB-1) te 
njegovih triju analoga (EB-2, EB-3 i EB-4) da smanji toksičnost CEES-a u humanih stanica epidermoidnog 
karcinoma (A-431). Vijabilnost stanica testirali smo s pomoću 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazol 
bromida (MTT) nakon 24-satne inkubacije s toksičnom koncentracijom CEES-a (1000 μmol L-1). 
Antioksidansi davani sami u različitim koncentracijama (15 μmol L-1, 30 μmol L-1, odnosno 60 μmol L-1) 
nisu smanjili vijabilnost stanica. Dvadesetčetverosatna primjena CEES-a i testiranih antioksidansa pokazala 
je da samo EB-1 i njegovi analozi EB-2, EB-3 i EB-4 mogu spriječiti smrt stanica, ali ne i stilbenski spojevi. 
EB-1 i EB-4 pokazali su se najdjelotvornijima u ublažavanju toksičnosti CEES-a u skladu s koncentracijom, 
dok su se EB-2 i EB-3 pokazali najmanje djelotvornima. Ovdje prikazani podaci upućuju na to da 
organoselenijevi antioksidansi, a napose EB-4, mogu biti korisni protuotrovi plikavcima.
KLJUČNE RIJEČI: CEES, EB-1, EB-2, EB-3, EB-4, humane stanice epidermoidnog karcinoma, MTT-
test, organoselenij, plikavci, protuotrov, pterostilben, resveratrol, vijabilnost stanica
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